ISS Backs Aptose-Hanmi Deal as Shareholders Face March 31 Vote
Event summary
- ISS recommends Aptose shareholders vote 'FOR' the $2.41 per share cash deal with Hanmi Pharmaceutical, citing a 28% premium and no competing bids.
- Special meeting reconvened for March 31, 2026 after SEC review delayed initial vote.
- Transaction includes corporate continuance from CBCA to ABCA governance.
- Proxy deadline set for March 27, 2026 with virtual shareholder meeting scheduled.
The big picture
The ISS recommendation validates the strategic rationale for Hanmi's acquisition of Aptose, positioning the deal as a rare premium offer in the current biotech M&A landscape. The transaction reflects broader consolidation trends among mid-cap oncology players seeking scale to support late-stage clinical programs. The corporate continuance component highlights governance flexibility considerations in cross-border pharmaceutical deals.
What we're watching
- Regulatory Approval
- Whether SEC and TSX clearance will proceed without further delays after initial transaction statement concerns.
- Shareholder Turnout
- The pace at which retail investors engage ahead of the March 27 proxy deadline following ISS endorsement.
- Integration Strategy
- How Hanmi plans to leverage Aptose's hematology-focused pipeline post-acquisition.
Related topics